In early 2026, BiomX Inc. fundamentally pivoted its business strategy from biopharmaceutical development to the advanced defense and security sectors by acquiring Israeli technology companies specializing in AI-powered surveillance and LADAR-based detection systems. The company discontinued its legacy phage therapy programs, replaced its management team, and now operates primarily through three subsidiaries focused on counter-UAS, perimeter security, and critical infrastructure protection. Despite initial revenue generation through Zorronet’s AI software platform and DFSL’s deployed LADAR systems, BiomX faces significant execution risks tied to integration, limited operating history in defense markets, supply chain dependencies, customer concentration, regulatory approvals, and financial constraints. Observers should monitor ongoing operational scaling, government contract wins, integration milestones, and regulatory compliance progress amid looming NYSE listing challenges.